Adam Yusim (@AdamYusimBio) header
Adam Yusim (@AdamYusimBio) profile picture

Hindsight is infallible. Real edge is knowing luck from skill and pressing high-conviction bets. Clinical-stage biotech and equity research. Not advice.

Canada
Joined May 2023
Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)
After digging deeper into the math, lab screenshots, and footnotes of Scorpion Capital's $ABVX report, the biggest flaws aren't in the loud headlines. They are buried in the fine print where Scorpion's own data directly contradicts its thesis. 🧵
2
6
2
53
3,079
Adam Yusim retweeted
$SLS $CAPR $RVMD $ABVX I have long been a proponent of activist short sellers despite their unpopularity, because historically they have found bad actors that others missed. But in these last 2 weeks, they've very effectively shown that they no longer serve any purpose in biotech. Over the last 2 weeks, we have had $CAPR with outright fraud, and $SLS that has very clearly hidden their SAP on the HR they released. Two very high profile, very sketchy situations. One already confirmed by the FDA as outright fraud, the other...TBD. Meanwhile, over that exact same period of time, what biotech short reports did we get? First, we got a $RVMD short report that basically said "Hey, their patients are dying"...somehow managing to ignore the fact that THE PATIENTS HAVE PANCREATIC CANCER. Then, when got an $ABVX short report that essentially said "Hey, this drug actually has NOT shown evidence of carcinogenicity in humans, but maybe someday it will!" These arguments were so week that it boggles the mind to believe that previously well-respected actors would ever publish them. Both of these "reports" were riddled with blatant inaccuracies and even more false equivalencies. And what were they attacking? They were going after two companies that were easily two of the most impressive stories biotech has generated throughout the 2020s. $RVMD moved the line further in pancreatic cancer than anyone has ever moved it before, with novel technology that they created! $ABVX salvaged a defunct HIV drug and discovered it was actually the most effective ulcerative colitis drug of all time (as measured by the now universally accepted key endpoint in UC - maintenance phase endoscopic remission). Two weeks. Two blatant fraud companies that the "activist short sellers" chose to completely ignore. Two short reports published to slander two of biotech's greatest beacons of success in this decade. Supposed activist short sellers used to actually look for fraud...now they just look for a widely owned name that has had success, make outrageous headline claims about it to cause a brief drop in the stock price, and put in the disclaimers section that they're actively covering their position on the drop they created. Shameful. Seriously shameful. The good news is, it won't work forever. When you beclown yourself like this enough times, everything you say stops having any impact. But man, the evolution of these "activist short sellers" from what they used to be into what they are today...what an embarrassment.
2
2
2
39
1,385
Scorpion calls the $ABVX obefazimod program a “fraud.” I went through the numbers behind that allegation. Start with the two that do the most work in the headline: 8.4× and 4×. The 8.4× tells us how far obefazimod’s UVA absorption exceeded a screening threshold for further photosafety assessment. Scorpion’s experiment did not measure damage to human skin, tumor formation or cancer risk. As far back as 2022, Abivax’s public protocol disclosed preclinical phototoxicity of the metabolite and called for dermatologic surveillance. That risk was under investigation four years before Scorpion published its report. The 4× comes from 4 nonmelanoma skin cancers among 195 patients on 50 mg, versus 1/192 on placebo, over 44 weeks of randomized maintenance. At 25 mg, it was 1/193. One detail matters: the placebo patient who developed skin cancer had received 50 mg during induction. Establishing whether the drug raises long-term cancer risk takes far more patients, years of exposure and an appropriate comparator. Scorpion also presents no evidence of oncogenic virus reactivation in these cases. Its own hypothesis centers on UVA exposure. Obefazimod’s efficacy in ulcerative colitis has been demonstrated. In two separate Phase 3 induction trials, clinical remission on 50 mg versus placebo was 21.7% vs 2.5% and 19.8% vs 6.3%. In the third Phase 3 trial, among induction responders, 50.8% on 25 mg and 51.3% on 50 mg were in remission at week 44, versus 10.4% on placebo. Endoscopy confirmed the benefit as well. If Scorpion is going to call three Phase 3 trials a fraud, show us which clinical data were falsified and how correcting them changes the result. I couldn’t find that evidence in 297 pages. We added to our $ABVX position at $65.
1
3
34
2,092
Continued: Yet Abivax already completed a positive Pre-NDA interaction with the FDA on July 30, 2026. A Pre-NDA meeting is specifically where the agency audits whether the clinical pharmacology, nonclinical, and Phase 3 packages are complete enough to file. $ABVX
Replying to @AdamYusimBio
Finally, notice the glaring regulatory omission. Scorpion predicts an FDA ambush over "missing" PK, ADME, and DDI studies. $ABVX
2
1
14
2,902
The only items that actually deserve investor focus ahead of the NDA are the clinical back-half questions: country-level sensitivity data outside China and Ukraine, full ICH S10 photosafety and skin lesion adjudication, and the complete FDA clinical pharmacology review. $ABVX
1
438
Everything else is noise designed to help a short seller cover on day one. $ABVX
1
2
420
Tazi's 2003 paper (p. 54): Scorpion calls a 2023 JCB "Retract and Replace" notice a sinister fraud where "ghost co-authors vanished," yet the pasted notice shows a 20-year-old plasmid error (S99P) where JCB upheld and republished the paper's core conclusions. $ABVX
1
1
475
Finally, notice the glaring regulatory omission. Scorpion predicts an FDA ambush over "missing" PK, ADME, and DDI studies. $ABVX
1
1
4
1,731